Holen Sie sich die Stockscreener-App
3.83
3.28%
-0.13
Handel nachbörslich:
3.95
0.12
+3.13%
Schlusskurs vom Vortag:
$3.96
Offen:
$3.96
24-Stunden-Volumen:
3.34M
Relative Volume:
1.05
Marktkapitalisierung:
$726.09M
Einnahmen:
Nettoeinkommen (Verlust:
$-196.48M
KGV:
-3.1502
EPS:
-1.2158
Netto-Cashflow:
$-183.16M
1W Leistung:
-4.96%
1M Leistung:
-2.79%
6M Leistung:
-34.08%
1J Leistung:
+27.45%
1-Tages-Spanne:
$3.78
$3.96
1-Wochen-Bereich:
$3.78
$4.135
52-Wochen-Spanne:
$2.54
$7.18
Annexon Inc Stock (ANNX) Company Profile
Firmenname
Annexon Inc
Sektor
Branche
Telefon
(650) 822-5500
Adresse
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
3.83 | 726.09M | 0 | -196.48M | -183.16M | -1.2158 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-13 | Hochstufung | Citizens | Mkt Underperform → Mkt Perform |
| 2026-07-21 | Eingeleitet | Citizens | Mkt Underperform |
| 2026-05-12 | Eingeleitet | Goldman | Neutral |
| 2025-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-30 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-05-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-09-16 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | BTIG Research | Buy |
| 2021-11-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-09-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-26 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | BofA Securities | Buy |
| 2020-08-18 | Eingeleitet | Cowen | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Annexon Inc Aktie (ANNX) Neueste Nachrichten
Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance Australia
Insider Spends US$100k Buying More Shares In Annexon - simplywall.st
After buying shares at a $3.83 average, Annexon (ANNX) CEO Love Douglas holds 390,476 shares. - Stock Titan
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting - Investing News Network
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com Nigeria
Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com South Africa
ANNX: Vonaprument's phase III trial in GA shows promise for vision preservation and broad market impact - TradingView
ANNX: Phase III GA study shows strong vision preservation, with high compliance and dual primary endpoints - TradingView
Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com UK
ANNX: Phase III programs in GBS and GA advance toward key data and regulatory milestones, with strong differentiation - TradingView
Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com India
Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com
Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com Canada
Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com UK
Annexon to Participate in Upcoming September Investor Conferences - Investing News Network
Annexon to Participate in Upcoming September Investor Conferences - finance.yahoo.com
ANNX Maintained by JP Morgan -- Price Target Raised to $14.00 - GuruFocus
ANNEXON, INC. : JP MORGAN RAISES TARGET PRICE TO $14 FROM $10 - Moomoo
ANNEXON, INC. : JP MORGAN RAISES TARGET PRICE TO $14 FROM $10 - Bitget
What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders - Yahoo Finance
Annexon (ANNX): Pipeline Momentum Is Building, but Cash Discipline Still Runs the Story - AlphaStreet
Annexon (ANNX) Quarterly Figures: The Available Earnings Metric Delivers a Beat in the Current Update; Share Response: The Stock Loses 4.55% in the Current UpdateMargin Guidance - vinanet.vn
Annexon (ANNX) Quarterly Figures: The Available Earnings Metric Delivers a Beat in the Current Update; Share Response: The Stock Loses 4.55% in the Current UpdateOne-Time Gain Impact - dars.gov.et
Annexon (ANNX) Q2 2026 Earnings Call Transcript - AOL.com
Annexon, Inc. Stock 12‑Month Price Target Raised to $15.71, Implies 198% Upside - TradingView
Annexon (ANNX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4) - marketscreener.com
Bank of America Corp DE Has $23.60 Million Stock Holdings in Annexon, Inc. $ANNX - MarketBeat
Annexon Inc (ANNX) Stock News Today - TradingKey
Annexon Inc (ANNX) Stock News Today - TradingKey
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
At $5.29, Annexon grants new employees options vesting over four years - Stock Titan
Annexon (ANNX) Adds Dual Primary Endpoint in Phase 3 Trial, Refl - GuruFocus
Annexon (ANNX) Earnings Call zu Q2 2026: ARCHER II erweitert, BLA-Einreichung im Zeitplan - TradingKey
Annexon (ANNX) Q2 2026 Earnings Call: ARCHER II Expanded, BLA Filing on Track - TradingKey
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Barchart.com
What is HC Wainwright's Estimate for Annexon Q3 Earnings? - MarketBeat
Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II TrialWhat's Changed - Sahm
Annexon (NASDAQ:ANNX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
ANNX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II TrialWhat's Changed - webull.com
State Street Corp Boosts Annexon Inc (ANNX) Stake by 42% in June Transaction - GuruFocus
A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $8 to $27 - Moomoo
Insider for ANNX (ANNX) plans sale of 2,000 shares after option exercise - Stock Titan
Annexon (ANNX), What Is Behind Its Latest Update? - Yahoo Finance
ANNX Upgraded by Citizens -- Rating Changed to Market Perform - GuruFocus
Annexon (NASDAQ:ANNX) Upgraded at Citizens Jmp - MarketBeat
BofA Securities Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Citizens upgrades Annexon stock rating on trial endpoint changes - Investing.com
Finanzdaten der Annexon Inc-Aktie (ANNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Annexon Inc-Aktie (ANNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WIGGANS THOMAS G | Former Director |
Aug 13 '26 |
Proposed Sale |
5.30 |
2,000 |
10,596 |
0 |
| WIGGANS THOMAS G | Former Director |
Jul 15 '26 |
Proposed Sale |
6.32 |
2,000 |
12,630 |
0 |
| WIGGANS THOMAS G | Former Director |
Jul 14 '26 |
Proposed Sale |
5.61 |
1,000 |
5,605 |
0 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Jun 11 '26 |
Option Exercise |
1.85 |
30,646 |
56,698 |
184,807 |
| Satter Muneer A | Director |
May 28 '26 |
Buy |
5.41 |
613,497 |
3,319,019 |
10,342,134 |
| Carson William H. | Director |
May 11 '26 |
Buy |
5.78 |
8,000 |
46,240 |
78,405 |
| Carson William H. | Director |
Apr 10 '26 |
Buy |
6.20 |
8,000 |
49,600 |
70,405 |
| Carson William H. | Director |
Mar 10 '26 |
Buy |
5.67 |
8,000 |
45,360 |
62,405 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Mar 02 '26 |
Sale |
5.42 |
4,339 |
23,517 |
182,625 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Mar 02 '26 |
Sale |
5.42 |
5,566 |
30,168 |
154,161 |
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):